Pre-surgery treatment with durvalumab plus chemotherapy for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of chemotherapy and an immunotherapy drug (durvalumab) given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with stomach cancer or gastroesophageal junction cancer that can be surgically removed.
- Your tumor is at a specific stage (cT2/3N+ or T4Nany, M0).
- You have not received any prior treatment for this cancer, such as chemotherapy or radiation.
- You are generally healthy enough to undergo chemotherapy before surgery (performance status 0 or 1).
- Your blood counts, liver, and kidney function are adequate, and you weigh more than 30 kg.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This study looks at tissue samples from stomach or gastroesophageal junction cancer to understand how the tumor interacts with its surroundings, which may help predict if the cancer will resist treatment. All participants will receive standard chemotherapy (FLOT) plus durvalumab before and after surgery.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial tests combining chemotherapy with an immunotherapy drug called durvalumab before and after surgery for stomach or lower esophagus cancer. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
Hear when a new Resectable Gasrtic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.